185 related articles for article (PubMed ID: 22170412)
61. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
62. What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?
Scheiman JM
Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):212-3. PubMed ID: 16265202
[No Abstract] [Full Text] [Related]
63. [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
Mateos JL
Drugs Today (Barc); 2010 Feb; 46 Suppl A():1-25. PubMed ID: 20224826
[TBL] [Abstract][Full Text] [Related]
64. Influence of Helicobacter pylori and omeprazole on celecoxib-induced gastroduodenal mucosal injury.
Ghosh B; Ghosh A
Indian J Gastroenterol; 2005; 24(4):177. PubMed ID: 16204915
[No Abstract] [Full Text] [Related]
65. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance.
Prieto A; De Barrio M; Martín E; Fernández-Bohórquez M; de Castro FJ; Ruiz FJ; Herrero T; Tornero P; Rubio M
J Allergy Clin Immunol; 2007 Apr; 119(4):960-4. PubMed ID: 17292954
[TBL] [Abstract][Full Text] [Related]
66. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
Micklewright R; Lane S; Linley W; McQuade C; Thompson F; Maskrey N
Aliment Pharmacol Ther; 2003 Feb; 17(3):321-32. PubMed ID: 12562444
[TBL] [Abstract][Full Text] [Related]
67. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial.
Rinder HM; Tracey JB; Souhrada M; Wang C; Gagnier RP; Wood CC
J Clin Pharmacol; 2002 Aug; 42(8):881-6. PubMed ID: 12162470
[TBL] [Abstract][Full Text] [Related]
68. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
Chan FK; Wong VW; Suen BY; Wu JC; Ching JY; Hung LC; Hui AJ; Leung VK; Lee VW; Lai LH; Wong GL; Chow DK; To KF; Leung WK; Chiu PW; Lee YT; Lau JY; Chan HL; Ng EK; Sung JJ
Lancet; 2007 May; 369(9573):1621-6. PubMed ID: 17499604
[TBL] [Abstract][Full Text] [Related]
69. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs.
Domingo MV; Marchuet MJ; Culla MT; Joanpere RS; Guadaño EM
J Investig Allergol Clin Immunol; 2006; 16(6):364-6. PubMed ID: 17153884
[TBL] [Abstract][Full Text] [Related]
70. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Elmets CA; Viner JL; Pentland AP; Cantrell W; Lin HY; Bailey H; Kang S; Linden KG; Heffernan M; Duvic M; Richmond E; Elewski BE; Umar A; Bell W; Gordon GB
J Natl Cancer Inst; 2010 Dec; 102(24):1835-44. PubMed ID: 21115882
[TBL] [Abstract][Full Text] [Related]
71. Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and piroxicam in rats.
Villegas I; Alarcón de la Lastra C; La Casa C; Motilva V; Martín MJ
Eur J Pharmacol; 2001 Feb; 414(1):79-86. PubMed ID: 11230998
[TBL] [Abstract][Full Text] [Related]
72. Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration.
Kuipers GK; Slotman BJ; Wedekind LE; Stoter TR; Berg Jv; Sminia P; Lafleur MV
Int J Radiat Biol; 2007 Oct; 83(10):677-85. PubMed ID: 17729162
[TBL] [Abstract][Full Text] [Related]
73. Multiple Colon Ulcers with Typical Small Intestinal Lesions Induced by Non-Steroidal Anti-Inflammatory Drugs.
Akashi M; Ando T; Hamashima T; Yoshita H; Nanjo S; Mihara H; Fujinami H; Kajiura S; Nishikawa J; Miura Y; Hosokawa A; Sugiyama T
Intern Med; 2015; 54(16):1995-9. PubMed ID: 26278290
[TBL] [Abstract][Full Text] [Related]
74. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Phillips RK; Wallace MH; Lynch PM; Hawk E; Gordon GB; Saunders BP; Wakabayashi N; Shen Y; Zimmerman S; Godio L; Rodrigues-Bigas M; Su LK; Sherman J; Kelloff G; Levin B; Steinbach G;
Gut; 2002 Jun; 50(6):857-60. PubMed ID: 12010890
[TBL] [Abstract][Full Text] [Related]
75. Are COX-2 inhibitors safe for anyone.
Bloomfeld RS
Inflamm Bowel Dis; 2006 Sep; 12(9):922-3. PubMed ID: 16954813
[No Abstract] [Full Text] [Related]
76. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
Sakamoto C; Soen S
Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
[TBL] [Abstract][Full Text] [Related]
77. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
[TBL] [Abstract][Full Text] [Related]
78. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
79. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.
Antoniou K; Malamas M; Drosos AA
Expert Opin Pharmacother; 2007 Aug; 8(11):1719-32. PubMed ID: 17685888
[TBL] [Abstract][Full Text] [Related]
80. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers.
Patoia L; Santucci L; Furno P; Dionisi MS; Dell'Orso S; Romagnoli M; Sattarinia A; Marini MG
Br J Rheumatol; 1996 Apr; 35 Suppl 1():61-7. PubMed ID: 8630640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
